GlobeNewswire: Melinta Therapeutics Contains the last 10 of 127 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:40:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/06/24/2052984/0/en/Melinta-Therapeutics-Announces-Termination-of-Merger-Agreement-and-Tender-Offer-for-Shares-of-Tetraphase.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase2020-06-24T20:02:00Z<![CDATA[MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common stock of Tetraphase (the “Offer”).]]>https://www.globenewswire.com/news-release/2020/06/09/2045917/0/en/Melinta-Therapeutics-Enters-Into-Agreement-to-Acquire-Tetraphase-Pharmaceuticals.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals2020-06-09T20:02:00Z<![CDATA[Company Enters Growth Phase in Hospital Market with Support of Deerfield]]>https://www.globenewswire.com/news-release/2020/03/04/1995373/0/en/Melinta-Therapeutics-Confirms-Deerfield-as-Successful-Bidder-for-Company.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company2020-03-04T21:03:00Z<![CDATA[Company Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support Company Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support]]>https://www.globenewswire.com/news-release/2020/02/13/1984894/0/en/Melinta-Therapeutics-Announces-Court-Approval-of-Chapter-11-Bidding-Procedures.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures2020-02-13T21:02:00Z<![CDATA[Bids due on March 2, 2020 by 4:00 p.m. Eastern Time]]>https://www.globenewswire.com/news-release/2019/12/27/1964654/0/en/Melinta-Therapeutics-Announces-Restructuring-Support-Agreement-with-its-Secured-Lenders-under-its-Senior-Credit-Facility.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility2019-12-27T14:02:00Z<![CDATA[Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations]]>https://www.globenewswire.com/news-release/2019/11/12/1945963/0/en/Melinta-Therapeutics-Files-Quarterly-Report-on-Form-10-Q-for-the-Quarter-Ended-September-30-2019.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 20192019-11-12T22:07:23Z<![CDATA[MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2019 with the Securities and Exchange Commission (“SEC”).]]>https://www.globenewswire.com/news-release/2019/10/24/1935314/0/en/Melinta-Therapeutics-Announces-U-S-FDA-Approval-of-Supplemental-New-Drug-Application-for-BAXDELA-delafloxacin-for-the-Treatment-of-Community-Acquired-Bacterial-Pneumonia-CABP.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)2019-10-24T20:02:00Z<![CDATA[~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~]]>https://www.globenewswire.com/news-release/2019/09/03/1910370/0/en/Melinta-Therapeutics-Announces-Appointment-of-Jennifer-Sanfilippo-to-Interim-Chief-Executive-Officer-and-Director.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director2019-09-03T20:05:00Z<![CDATA[MORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta.]]>https://www.globenewswire.com/news-release/2019/08/09/1899887/0/en/Melinta-Therapeutics-Names-David-Gill-as-Chairman-and-Announces-CEO-Succession-Plan.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan2019-08-09T11:31:00Z<![CDATA[Company Initiates Search for New Chief Executive Officer Company Initiates Search for New Chief Executive Officer]]>https://www.globenewswire.com/news-release/2019/08/09/1899883/0/en/Melinta-Therapeutics-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=20265Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update2019-08-09T11:30:00Z<![CDATA[~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~]]>